Olumide Gbolahan
Overview
A board certified medical oncologist, Dr. Gbolahan specializes in the treatment of gastrointestinal cancers, particularly biliary tract, liver and pancreatic malignancies. Dr. Gbolahan joined the clinical staff at Winship Cancer Institute as a practicing physician in October 2021.
Dr. Gbolahan received his Medical Degree from University of Ibadan in Nigeria. His postgraduate medical education included residency training at Morehouse School of Medicine in Atlanta, Georgia. He completed his fellowship in hematology/oncology at Indiana University School of Medicine. He received his MSc in Cancer Immunology and Biotechnology from University of Nottingham.
Dr. Gbolahan's research focus is in early and late drug development and in translational research for hepatobiliary and pancreatic malignancies.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MBBS from University of Ibadan
- MSc from University of Nottingham
Research
Publications
-
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.
Oncoimmunology Volume: 14 Page(s): 2475620
12/01/2025 Authors: Phillips MJ; Alese OB; Horvat NK; Greene E; Gbolahan OB; Coleman K; Doxie DB; Parihar V; Mahdi ZK; McCook-Veal A -
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations.
Oncologist Volume: 30
06/04/2025 Authors: Wheless MC; Zemla TJ; Hubbard JM; Strickler JH; Gbolahan OB; Wilson L; Waechter B; Ou F-S; Nixon AB; Bekaii-Saab TS -
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.
Cancer Res Commun Volume: 5 Page(s): 896 - 905
06/01/2025 Authors: Carneiro BA; Gbolahan OB; Abdul Razak AA; Hilton JF; Lambert AW; Hood J; Pluta M; Bragulat V; Sanai E; Kumar R -
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.
Future Oncol Volume: 21 Page(s): 1357 - 1363
05/01/2025 Authors: Grewal US; Gbolahan OB; Takalkar AM; Halperin DM -
Feasibility and Safety of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Neuroendocrine Tumor in a Patient With Sickle Cell Anemia.
Clin Nucl Med
03/03/2025 Authors: Lawal IO; Gbolahan OB; Marcus C; Jones AT; Shaib WL; Muzahir S -
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma.
Endocr Relat Cancer Volume: 31
10/01/2024 Authors: McDonald A; Avadhani V; Oprea-Ilies G; Zakka K; Lesinski GB; Gbolahan OB; Alese O -
Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer.
JAMA Netw Open Volume: 7 Page(s): e2351502
01/02/2024 Authors: Gbolahan OB; Zhi X; Liu Y; Shah MM; Kooby DA; Alese OB -
Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
Curr Oncol Volume: 30 Page(s): 10100 - 10110
11/25/2023 Authors: Villalobos A; Dabbous HH; Little O; Gbolahan OB; Akce M; Lilly MA; Bercu Z; Kokabi N -
Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
Volume: 149 Page(s): 8673 - 8680
09/01/2023 Authors: Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N -
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Lancet Oncol Volume: 24 Page(s): 772 - 782
07/01/2023 Authors: Harding JJ; Fan J; Oh D-Y; Choi HJ; Kim JW; Chang H-M; Bao L; Sun H-C; Macarulla T; Xie F